Building a pipeline for novel therapies in castrate-resistant disease: the SRF paradigm

Key Information

Cancer type: 
Research Institution: 
Grant Amount: 
Start date: 
December 1, 2012
End date: 
July 31, 2017

Scientific Project Abstract

Prostate cancer is the most common non-cutaneous solid organ malignancy among men. While early detection allows for curative therapies, advanced disease represents a challenge to treat with no effective treatment options available. Previous studies by our laboratory have shown that there are many changes occurring in a cancer cell which help it to resist current therapies. While trying to manipulate all these changes proves difficult, targeting the central factors that regulate them would seem a more appropriate therapeutic approach. We have previously identified one of these factors, the Serum Response Factor (SRF), showing that SRF manipulation has an impact on the ability of prostate cancer cells to proliferate and die. The objective of this study is to test SRF as a possible target for novel drugs which will improve advanced prostate cancer treatment. With this proposal we aim to: 1) expand our understanding of the mechanisms by which SRF is able to impact on prostate cancer cells' survival' 2) use a mouse model of prostate cancer to test SRF as a possible target, by manipulating it with a drug called CCG1423. If successful this will lead to clinical trials of this new drug, urgently needed for advanced prostate cancer treatment.

For the non-scientist

One-line description: 
Examination of the SRF molecule as a potential drug target for prostate cancer
What this project involves: 

Advanced prostate cancer is a disease with very few treatment options which is extremely difficult to treat. This project aims to test a protein called SRF as a therapeutic target for advanced prostate cancer. Within this study, the mechanism of action of SRF on prostate cancer survival will be examined, and preclinical testing of a SRF-targeting drug will be performed. If successful this may lead to clinical trials of a new drug for the treatment of advanced prostate cancer.